October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for…
To unveil talents and transform societies PARIS, Oct. 9, 2025 /PRNewswire/ -- Autumn 2025 marks a pivotal moment for SKEMA…
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
Official manufacturing sponsor of Amazon Beauty in Seoul 2025, attracting over 3,000 online and offline participants Vice Chairman Sang-Hyun Yoon…
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…
ISTANBUL, Sept. 5, 2025 /PRNewswire/ -- As the world's largest home and consumer technology event, IFA Berlin once again brings…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…